Tag Archives: personalized medicine

Rayno Life Sciences: First Half Stock Performance Part 2-ILMN, SQNM

Rayno Diagnostics and Tools-Sequencing Rules Diagnostics and Tools stocks tracked biotech stocks during the huge moves in January/February and sold off until the April bottom. However stocks that are more revenue and earnings driven -Cardiovascular Systems(CSII) and Quidel (QDEL)- did not recover to former highs. Sequenom  (SQNM) is a leader in non-invasive pre-natal tests such […]

Comments Off Continue Reading →

Clinical Tools and Diagnostic Companies:Financial Metrics 2014 Q1Results

Clinical Diagnostic Stocks Were Hit By Bio-Bubble or Revenue Miss Potential upside in EXAS, NSTG and NEOG all are Rayno Dx and Tools picks. With “momentum trading” days over for now, revenue growth is the focus. Companies with disappointing Q1 revenues: Abaxis (ABAX), Alere (ALR), Response Genetics (RGDX) and Quidel (QDEL). Q2 recovery will be key. […]

Comments Off Continue Reading →

Rayno Biopharmaceutical Portfolio Nov. 1, 2013 YTD Performance

Rayno 2013 Picks Outperform Biotechnology Indices and Funds  Biopharmaceutical stocks hit all time highs in 2013 with major ETFs up as follows YTD: FBT ($65) up 41%, IBB ($206) up 50%, and XBI ((%120) up 36%. The Five Star Fidelity Select Biotechnology Fund (FBIOX $171) is up 54.5% YTD. You can see our top picks […]

Comments Off Continue Reading →

Biotech Stocks Have A Bit of a MO-Off Day: AEGR, PCYC, MDVN, REGN

Biotech Stocks Take A Breather: NASDAQ off 0.3% at 3597 A little profit taking has set in after it seemed that the market would roar all summer. From the action in mid-cap biopharma stocks it looks like hedge funds are taking some off among high flyers.NASDAQ has been up for 14 straight days or 18% […]

Comments Off Continue Reading →

ASCO Day 2 Briefs and Daily Movers: ARRY,GILD,IBB,IMGN,SGEN

Apparently ASCO Is “Sell On the News” Trigger Another lackluster trading day with profit taking; the IBB  is down 2.3% and trading near its May bottom with a pronounced topping pattern.Moreover many funds and indices now own biotech stocks so without the general market rallying ((NASDAQ off 22 pts at 2:30 p EDT), the sector will […]

Comments Off Continue Reading →

Reiterate Caution on Biopharmaceutical Stocks With Major 3% Sector Sell-Off

Raise More Cash- No Change in Rayno Biopharma Portfolio Last month we raised the yellow flag on the biotech sector because of a choppy tape, new highs with weakness in MO (Momentum) plays and the anticipation of ASCO news that could trigger a “sell on the news” trend. Moreover CNBC pundits have been pushing biotech […]

Comments Off Continue Reading →